ClinicalTrials.gg
RecruitingNCT07438028SeasonUpdated Nov 12, 2026

Energy Reduction and Umami

An interventional study of Regular energy density, no added umami and Regular energy density, with added umami in Sensory Testing, Umami Taste and Energy Density, sponsored by Wageningen University. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Wageningen University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

People tend to regulate intake by the weight of food rather than its energy content, making energy dense foods, especially those combining salty, fatty, and umami tastes, more likely to promote passive overconsumption. Lowering energy density can reduce daily energy intake, but often decreases palatability, whereas umami can enhance palatability, and sometimes decrease food intake. This suggests that adding umami to a regular energy dense diet could reduce food intake over time, and that adding umami to a reduced energy dense diet could sustain palatability and limit compensatory energy intake. Therefore, the aim of this study is to assess the effect of a 2-week dietary intervention of adding umami and/or lowering energy density on food intake. Secondary objectives are whether adding umami and/or lowering energy density affect dietary satisfaction, appetite, perceived umami intensity, food preferences, bodyweight and composition, and wellbeing ratings.

This will assessed in a double-blind crossover, randomized controlled trial of three times two weeks, each separated by two weeks washout in 33 healthy Dutch adults between 18-65 years of age, with a BMI between 20-30. Umami taste will be added through MSG supplementation of the three main meals. Supplementation will depend on both intervention group, and individual participants' body weight. Energy density will be lowered by swapping regular products for low-fat, low-sugar or higher water products.

The three intervention diets will vary in umami taste intensity, and/or energy density: 1) regular energy density without added umami (control), 2) regular energy density with added umami, 3) reduced energy density with added umami. Umami will be supplemented by supplementing food items with 55-60 mg MSG per kg bodyweight daily, divided over three eating occasions. Foods will be offered ad libitum, and participants will add a seasoning sachet containing MSG to their selected portion.

The primary objective will be to compare average daily food intake (kcal) over two weeks between the three dietary interventions differing in umami taste intensity and energy density. Secondary outcomes are dietary satisfaction, appetite, perceived umami intensity, food preferences, bodyweight and composition, and wellbeing ratings.

02

Conditions studied

  • Sensory Testing
  • Umami Taste
  • Energy Density
  • Food Intake Measurement

Keywords

  • umami
  • taste
  • intensity
  • ad libitum
  • intake
  • reduced energy
03

In context

Lead sponsor

Wageningen University is the lead sponsor of 153 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy: as judged by the participant;
  • Age 16-65 years at the time of inclusion, assessed by date of birth;
  • Proper understanding of the Dutch language, as questionnaires will be in Dutch;
  • Able to visit Wageningen University, as required for dietary intervention and testing;
  • 20-30 kg/m2;
  • Having normal taste ability, assessed using Mueller taste strip test, ≥12 out of 20 assessed correctly.

Exclusion criteria

Exclusion Criteria:

  • Suffering from endocrine- or gastro-intestinal diseases or other diseases that might influence study outcomes (such as diabetes, Crohn's disease, cardiovascular disease, hypertension, etc.);
  • Diagnosed with eating disorders (currently or in the past);
  • Diagnosed with taste or smell disorders in the past six months;
  • Pregnant or lactating during the study intervention;
  • Following a strict dietary regime;
  • Extreme physical activity (>10 hours per week moderate/high intensity exercise);
  • Gain or loss of more than 5 kgs in the last six months prior to study entry;
  • Suffering from lack of appetite for any reason;
  • Use of medication that may influence the appetite (medication will be judged by the medical investigator);
  • Having a food allergy and/or intolerance for foods used in the dietary intervention (e.g. lactose intolerance, gluten intolerance, MSG sensitivity). This will be assessed with an open question;
  • Consumes more than 14 (women) or 21 (men) glasses of alcohol per week;
  • Consumes MSG-rich sauces (soy sauce, ketjap and/or curry paste) more than once per day, or consumes more than 3 savoury food items (paprika chips, instant noodles, sundried tomatoes and/or pre-packaged seasonings) per day. This will be assessed with a frequency of consumption table;
  • Irregular eating pattern. This will be measured with a frequency of meal/food consumption table, and is defined as: frequency of breakfast consumption less than once per week;
  • Unwilling to maintain regular exercise pattern during the study period. This will be assessed with a yes/no question;
  • Unwilling to quit use of soft or hard drugs during the intervention;
  • Student or personnel of the division of Human Nutrition and Health, Wageningen University;
  • Participating in any other intervention study/studies or planning to participate in another intervention study during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    regED/-MSG -> regED/+MSG -> lowED/+MSG

    Participants receive Intervention regED/+MSG in Period 1, Intervention regED/-MSG in Period 2, and Intervention lowED/+MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

  • Experimental
    regED/-MSG -> lowED/-MSG -> regED/+MSG

    Participants receive Intervention regED/-MSG in Period 1, Intervention lowED/+MSG in Period 2, and Intervention regED/+MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

  • Experimental
    regED/+MSG -> lowED/+MSG -> regED/-MSG

    Participants receive Intervention regED/+MSG in Period 1, Intervention lowED/+MSG in Period 2, and Intervention regED/-MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

  • Experimental
    regED/+MSG -> regED/-MSG -> lowED/+MSG

    Participants receive Intervention regED/+MSG in Period 1, Intervention regED/-MSG in Period 2, and Intervention lowED/+MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

  • Experimental
    lowED/+MSG -> regED/+MSG -> regED/-MSG

    Participants receive Intervention lowED/+MSG in Period 1, Intervention regED/+MSG in Period 2, and Intervention regED/-MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

  • Experimental
    lowED/+MSG -> regED/-MSG -> regED/+MSG

    Participants receive Intervention lowED/+MSG in Period 1, Intervention regED/-MSG in Period 2, and Intervention regED/+MSG in Period 3.

    Other: Regular energy density, no added umami · Other: Regular energy density, with added umami · Other: Lowered energy density, with added umami

Interventions

  • OtherRegular energy density, no added umami

    During this intervention, participants will receive a Dutch diet with regular energy density, without added umami (MSG)

    Also known as: regED/-MSG

  • OtherRegular energy density, with added umami

    During this intervention, participants will receive a Dutch diet with regular energy density, with added umami (MSG). Added umami will represent Dutch MSG intake levels of around the 95th percentile, which is about 55-60 mg/kg body weight.

    Also known as: regED/+MSG

  • OtherLowered energy density, with added umami

    During this intervention, participants will receive a Dutch diet with lowered energy density, with added umami (MSG). Energy density will be lowered by substituting regular products for lower-fat, lower-sugar or higher water versions. Added umami will represent Dutch MSG intake levels of around the 95th percentile, which is about 55-60 mg/kg body weight.

    Also known as: lowED/+MSG

06

What researchers measure

Primary outcomes

  1. Food intake (kcal)

    Difference between interventions in daily food intake, averaged over two weeks. Food intake is defined as total daily energy intake from meal, snack and drink consumption. Food intake will be measured by weighing breakfast, lunch and dinner intake in grams, which will be converted to energy (kcal). Snack and drink consumption will be recorded and converted to energy (kcal) as well. Food intake is measured daily, and averaged over each intervention.

    Time frame: From start to end of each intervention (day 1-14, day 29-42 and day 57-72).

Secondary outcomes

  1. Dietary satisfaction

    Difference in dietary satisfaction scores between interventions, measured with the dietary satisfaction questionnaire (DSat-45). Difference between dietary satisfaction scores will be compared between the three interventions.

    Time frame: Measured at day 14 (end) of each intervention.

  2. Appetite and thirst ratings

    Appetite and thirst ratings will be measured six times daily (before three main meals and at three random times each day). Difference between average appetite and thirst ratings will be compared between the three interventions.

    Time frame: From start to end of each intervention (day 1 to day 14, day 19 to day 42 and day 56 to day 70).

  3. Taste Preference

    Preference for sweet/fa, sweet, salt/fat and salt tastes will be measured using PrefQuest at the end of each intervention (day 14). Differences of preferences for these tastes will be compared between the three interventions.

    Time frame: Measured at day 14 (end) of each intervention.

  4. Perceived umami taste intensity

    Perceived umami taste intensity will be measured at the end of each intervention during a sensory test, during which participants will rate their perceived umami taste intensity of samples differing in food type (solid, semi-solid, liquid) and MSG concentration. Differences in perceived umami taste intensity will be compared between the three interventions.

    Time frame: Measured at day 14 (end) of each intervention.

  5. Fat mass

    Changes in fat mass will be measured using Bioelectrical Impedance Analysis (BIA), and compared between the three interventions.

    Time frame: Six times during each intervention (day 1, 3, 6, 8, 12 and 14).

  6. Bodyweight

    Changes in bodyweight will be measured using a calibrated scale, and compared between the three interventions.

    Time frame: Six times during each intervention (day 1, 3, 6, 8, 12 and 14).

  7. Differences in MSG complex syndrome related complaints

    MSG syndrome complex related complaints will be assessed daily using an MSG tolerance questionnaire. Number of reported complaints in differences of MSG complex syndrome related complaints will be compared between the three interventions.

    Time frame: From start to end of each intervention (day 1-14, day 29-42 and day 57-72)

  8. Difference in adverse events or medication use

    The difference in Adverse events occurence, or medication use between intervention groups at the end of each intervention, adjusted for baseline differences. This will be measured daily by a questionnaire.

    Time frame: From start to end of each intervention (day 1-14, day 29-42 and day 57-72)

  9. Difference between change in food intake over time

    Difference between interventions in the day-to-day pattern of food intake across the two-week intervention periods. Food intake is defined as total daily energy intake from meal, snack and drink consumption. Food intake will be measured by weighing breakfast, lunch and dinner intake in grams, which will be converted to energy (kcal). Snack and drink consumption will be recorded and converted to energy (kcal) as well. Food intake is measured daily, and averaged over each intervention.

    Time frame: From start to end of each intervention (day 1-14, day 29-42 and day 57-72).

Other outcomes

  1. MSG consumption

    MSG will be administered based on intervention group and bodyweight of each individual participant. Daily MSG consumption will be measured by asking participants to return empty sachets that contained the MSG supplementation. Differences in MSG consumption between the interventions will be reported as a compliance measure.

    Time frame: From start to end of each intervention (day 1-14, day 29-42 and day 57-72)

  2. Sex

    Based on self-report in the screening questionnaire. Baseline characteristic.

    Time frame: Baseline (day 0)

  3. Age

    Based on self-report in the screening questionnaire. Baseline characteristic.

    Time frame: Baseline (day 0)

  4. Height

    Will be assessed using a stadiometer as the average of two measurements, rounded to the closest decimal. This will be done during the physical screening session.

    Time frame: Baseline (day 0)

  5. Baseline medicine usage

    Based on self-report in the screening questionnaire. Baseline characteristic.

    Time frame: Baseline (day 0)

  6. Smoking status

    Based on self-report in the screening questionnaire. Baseline characteristic.

    Time frame: Baseline (day 0)

  7. Dietary restraint score

    Measured by the Dutch Eating Behaviour Questionnaire (DEBQ).

    Time frame: Baseline (day 0)

  8. Dietary taste patterns

    Measured by Food Frequency Questionnaire designed to classify people on taste consumption patterns (tasteFFQ). Results will be used to describe habitual food intake based on taste (relative food intake in grams of each taste) at baseline.

    Time frame: Baseline (day 0)

  9. Physical activity level

    Measured using the SQUASH questionnaire with a reference period of two weeks. This is a compliance measure as participants are asked to maintain stable exercise patterns during the study period. Physical activity will be reported as a along with descriptive measures of participant characteristics.

    Time frame: Measured at day 14 (end) of each intervention.

07

Study locations

1 of 1 sites recruiting
  • Department of Human Nutrition, Wageningen University
    Wageningen, Gelderland 6708WE, Netherlands
    Recruiting
08

References and documents

Publications

  • James BL, Loken E, Roe LS, Myrissa K, Lawton CL, Dye L, Rolls BJ. Validation of the Diet Satisfaction Questionnaire: a new measure of satisfaction with diets for weight management. Obes Sci Pract. 2018 Oct 10;4(6):506-514. doi: 10.1002/osp4.299. eCollection 2018 Dec. PubMed 30574344 ↗
  • Terpstra SES, Hoogervorst LA, van der Velde JHPM, Mutsert R, van de Stadt LA, Rosendaal FR, Kloppenburg M. Validation of the SQUASH physical activity questionnaire using accelerometry: The NEO study. Osteoarthr Cartil Open. 2024 Mar 18;6(2):100462. doi: 10.1016/j.ocarto.2024.100462. eCollection 2024 Jun. PubMed 38577551 ↗
  • Dalton M, Finlayson G, Hill A, Blundell J. Preliminary validation and principal components analysis of the Control of Eating Questionnaire (CoEQ) for the experience of food craving. Eur J Clin Nutr. 2015 Dec;69(12):1313-7. doi: 10.1038/ejcn.2015.57. Epub 2015 Apr 8. PubMed 25852028 ↗
  • Mueller C, Kallert S, Renner B, Stiassny K, Temmel AF, Hummel T, Kobal G. Quantitative assessment of gustatory function in a clinical context using impregnated "taste strips". Rhinology. 2003 Mar;41(1):2-6. PubMed 12677732 ↗
  • Masic U, Yeomans MR. Umami flavor enhances appetite but also increases satiety. Am J Clin Nutr. 2014 Aug;100(2):532-8. doi: 10.3945/ajcn.113.080929. Epub 2014 Jun 18. PubMed 24944058 ↗
  • Bellisle F. Experimental studies of food choices and palatability responses in European subjects exposed to the Umami taste. Asia Pac J Clin Nutr. 2008;17 Suppl 1:376-9. PubMed 18296383 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underline the results reported in an article after de-identification will be shared.

Supporting information: Statistical analysis plan, Analytic code

Time frame: Following the publication. No end date.

Access criteria: Anyone who whishes to access the data for secondary analysis must contact corresponding authors of specific publications for their approval. Next to this, they must reference the source of the data to provide appropriate credit to those who generated the data and allow searching for the studies it has supported.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Apr 2027, 2 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Sep 2026 → Feb 2027, primary completion Dec 2026 → Apr 2027 and completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartEst.
Feb 11, 2027was Sep 2026
Primary completionEst.
Apr 2027was Dec 2026
CompletionEst.
Apr 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
Department of Human Nutrition, Wageningen University is now Recruiting
Nov 12, 2026
Start date
Sep 2026→Feb 11, 2027
Nov 12, 2026
Primary completion
Dec 2026→Apr 2027
Nov 12, 2026
Study completion
Dec 2026→Apr 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    Department of Human Nutrition, Wageningen University is now Recruiting
    Start date Sep 2026→Feb 11, 2027
    Primary completion Dec 2026→Apr 2027
    Study completion Dec 2026→Apr 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07438028
Collaborators
Ajinomoto Co., Inc.
Responsible party
Ciaran Forde (Prof. Dr., Wageningen University) — Principal investigator
First posted
Feb 27, 2026
Start date
Feb 11, 2027 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Merel J. van der Kruijssen, Msc
Contact
merel.vanderkruijssen@wur.nl
+31 6 1289431
Monica Mars, Dr. Ir.
Contact
monica.mars@wur.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion